Medicine and HealthCommunications Biology
An engineered ACE2 decoy neutralizes SARS-CoV-2 Omicron BA.5 in vitro and in vivo
H. B., L. G. W., et al.
SARS-CoV-2 continues to evolve, challenging antibody responses. Researchers, including Havranek, Lee, Procko, and others, have developed FLIF, a soluble ACE2 decoy that showcases remarkable neutralization capabilities against the Delta and Omicron variants, including BA.5. This innovative approach has the potential to serve as a therapeutic solution for coronaviruses.
Related Publications
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Medicine and Health
Engineered ACE2 decoy mitigates lung injury and death induced by SARS-CoV-2 variants
L. Zhang, S. Dutta, et al.
Medicine and Health
Sulforaphane exhibits antiviral activity against pandemic SARS-CoV-2 and seasonal HCoV-OC43 coronaviruses in vitro and in mice
A. A. Ordonez, C. K. Bullen, et al.
Medicine and Health
Variant-proof high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways
M. Gagne, B. J. Flynn, et al.
Medicine and Health
Updated vaccine protects against SARS-CoV-2 variants including Omicron (B.1.1.529) and prevents transmission in hamsters
S. Sharma, T. Vercruysse, et al.
